Baxter International Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Baxter International Inc. on February 21, 2020. The report details an "Other Event" (Item 8.01) concerning amendments to the Company's credit facilities and related guarantees.
Key Financial Metrics
The filing does not provide specific revenue, profit, cash flow, margin, or liquidity figures for the reporting period. It references the following credit facility amounts:
- Revolving Credit Agreement: $2.0 billion (five-year term, dated December 20, 2019).
- Guaranteed Credit Agreement: €200 million (five-year term, dated December 20, 2019, for Baxter Healthcare SA and Baxter World Trade SPRL).
Material Changes
The primary material change is the execution of Amendment No. 1 to both the $2.0 billion revolving credit agreement and the associated guaranty. These amendments extend the deadline for delivering financial statements to the lenders:
- Quarterly Statements: For the fiscal quarter ended September 30, 2019.
- Annual Statements: For the fiscal year ended December 31, 2019.
- New Delivery Deadline: March 31, 2020.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, or discussion of risks and contingencies beyond the administrative extension of financial reporting deadlines to the credit agreement lenders.
Investor Verification Checklist
- Verify the reasons for the extension of financial statement delivery dates to lenders.
- Review the upcoming 10-Q and 10-K filings to confirm the actual financial performance for the periods ending September 30, 2019, and December 31, 2019.
- Confirm that no other covenants were breached or amended alongside the delivery date extension.